Idazoxan Hydrochloride structure
|
Common Name | Idazoxan Hydrochloride | ||
|---|---|---|---|---|
| CAS Number | 79944-56-2 | Molecular Weight | 240.68600 | |
| Density | N/A | Boiling Point | 397ºC at 760 mmHg | |
| Molecular Formula | C11H13ClN2O2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 193.9ºC | |
| Symbol |
GHS06 |
Signal Word | Danger | |
Use of Idazoxan HydrochlorideIdazoxan hydrochloride (RX 781094 hydrochloride) is an α2-adrenoceptor antagonist and is also a imidazoline receptors (IRs) antagonist competitively antagonized the centrally induced hypotensive effect of imidazoline-like drugs (IMs). Idazoxan hydrochloride also improves motor symptoms in Parkinson’s disease, L-DOPA-induced dyskinesias, and experimental Parkinsonism[1][2]. |
| Name | Idazoxan hydrochloride,2-(1,4-Benzodioxan-2-yl)-2-imidazolinehydrochloride |
|---|---|
| Synonym | More Synonyms |
| Description | Idazoxan hydrochloride (RX 781094 hydrochloride) is an α2-adrenoceptor antagonist and is also a imidazoline receptors (IRs) antagonist competitively antagonized the centrally induced hypotensive effect of imidazoline-like drugs (IMs). Idazoxan hydrochloride also improves motor symptoms in Parkinson’s disease, L-DOPA-induced dyskinesias, and experimental Parkinsonism[1][2]. |
|---|---|
| Related Catalog | |
| Target |
α2-adrenoceptor[1]; Imidazoline receptors (IRs)[2] |
| In Vivo | Idazoxan (0.16-5 mg/kg; subcutaneous injection; for 1 hour; male CD-COBS rats) treatment potently reverses haloperidol-induced catalepsy with an ED50 of 0.25 mg/kg. Idazoxan (0.3 and 2.5 mg/kg) has no effect on extracellular DA and do not modify the rise of extracellular DA induced by haloperidol[1]. Animal Model: Male CD-COBS rats injected with 1 mg/kg haloperidol[1] Dosage: 0.16 mg/kg, 0.31 mg/kg, 0.63 mg/kg, 1.25 mg/kg, 2.5 mg/kg, and 5.0 mg/kg Administration: Subcutaneous injection; for 1 hour Result: Potently reversed haloperidol-induced catalepsy with an ED50 of 0.25 mg/kg. |
| References |
| Boiling Point | 397ºC at 760 mmHg |
|---|---|
| Molecular Formula | C11H13ClN2O2 |
| Molecular Weight | 240.68600 |
| Flash Point | 193.9ºC |
| Exact Mass | 240.06700 |
| PSA | 42.85000 |
| LogP | 1.39450 |
| InChIKey | MYUBYOVCLMEAOH-UHFFFAOYSA-N |
| SMILES | Cl.c1ccc2c(c1)OCC(C1=NCCN1)O2 |
| Symbol |
GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301 |
| Precautionary Statements | P301 + P310 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
| Hazard Codes | Xn: Harmful; |
| Risk Phrases | 22 |
| Safety Phrases | 7 |
| RIDADR | UN 2811 6.1/PG 3 |
|
~81%
Idazoxan Hydroc... CAS#:79944-56-2 |
| Literature: Bougaret, Joel; Avan, Jean-Louis; Segonds, Roland Patent: US2005/90537 A1, 2005 ; Location in patent: Page/Page column 8; 9 ; |
|
~%
Idazoxan Hydroc... CAS#:79944-56-2 |
| Literature: Tetrahedron Letters, , vol. 22, # 48 p. 4839 - 4842 |
|
~%
Idazoxan Hydroc... CAS#:79944-56-2 |
| Literature: Tetrahedron Letters, , vol. 22, # 48 p. 4839 - 4842 |
|
~%
Idazoxan Hydroc... CAS#:79944-56-2 |
| Literature: Tetrahedron Letters, , vol. 22, # 48 p. 4839 - 4842 |
|
The timing of dopamine- and noradrenaline-mediated transmission reflects underlying differences in the extent of spillover and pooling.
J. Neurosci. 34(22) , 7645-56, (2014) Metabotropic transmission typically occurs through the spillover activation of extrasynaptic receptors. This study examined the mechanisms underlying somatodendritic dopamine and noradrenaline transmi... |
|
|
Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3 -adrenoceptor activation and α1 -adrenoceptor blockade.
Br. J. Pharmacol. 173 , 415-28, (2016) This article is commented on by Michel, M. C., pp. 429-430 of this issue. To view this commentary visit http://dx.doi.org/10.1111/bph.13379.Mirabegron is the first β3 -adrenoceptor agonist approved fo... |
|
|
Chemical stimulation of the ST36 acupoint reduces both formalin-induced nociceptive behaviors and spinal astrocyte activation via spinal alpha-2 adrenoceptors
Brain Res. Bull. 86(5-6) , 412-21, (2011) Highlights ► DBV's anti-nociceptive effect involves suppression of spinal astrocyte activation. ► DBV-induced astrocyte inhibition is mediated by spinal alpha-2A and alpha-2C adrenoceptors. ► Astrocyt... |
| Idazoxan Hydrochloride |
| Melanotan II |
| IdazoxanHCl |